SLC29A1 and pancreatic neoplasm: Since many clinical studies showed that a low expression of hENT1 was associated with a poor survival of pancreatic cancer patients receiving gemcitabine [97–99], Clavis Pharma developed an elaidic acid prodrug modified at the 5′-sugar position, CP-4126, which was able to bypass hENT1.